Board of Directors

Industry Leaders and Veterans Guiding Company Strategy

You are here: Home / Company / Board of Directors

Edico Genome’s Board of Directors comprises a diverse mix of veterans from the life sciences, genomics and technology industries.

Pieter van Rooyen Ph.D.

Edico Genome

Pieter has more than 20 years of experience inventing, developing and successfully commercializing technologies in industries including semiconductors, wireless, health care, life sciences, image processing and retail automation, with a portfolio of over 130 granted patents in these areas. His passion for bringing to market innovative technologies has led to the formation and funding of a number of technology start-ups with significant return to investors. Prior to Edico Genome, Pieter was involved in the emerging mobile health industry where mobile phone technology enables innovative health care delivery in underdeveloped communities. Pieter also co-founded ecoATM (acquired in 2013 by Outerwall (NASDAQ:OUTR) for $350 mil.) and Zyray Wireless (acquired in 2004 by Broadcom Corporation (NASDAQ:BRCM) for $100 mil.).

Greg Lucier

Thermo Fisher Scientific/Life Technologies and NuVasive

From May 2003 to February 2014, Mr. Lucier served as Chairman and Chief Executive Officer of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific in 2014.  Gregory T. Lucier has served as a member of the NuVasive Board of Directors since December 2013.  During Mr. Lucier’s 11-year tenure at Life Technologies, he led the company from a small start-up known as Invitrogen in 2003, directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies, and then transformed the organization by 2013 into a global, world-leading biotechnology firm with 50,000 products, 12,000 employees and nearly $4 billion in sales in more than 180 countries.  Serving in his leadership role, Mr. Lucier was responsible for fostering a culture of excellence at Life Technologies and applied his more than 25 years of strategic management experience to help champion an era of personalized medicine.  Mr. Lucier previously was a Corporate Officer of General Electric and served as an executive at GE Medical Systems. He received a bachelor’s degree in engineering from Pennsylvania State University and a masters of business administration from Harvard Business School.

Kenneth Buechler Ph.D.

Biosite and Sequenom

Dr. Kenneth F. Buechler, co-Founded Biosite Inc. where he served as President and Chief Scientific Officer. He is a Co-inventor of certain Biosite proprietary technologies, including the Triage® Drugs of Abuse Panel and the Triage® Meter Plus platform. Prior to Biosite Inc., he served as a Senior Research Scientist of the Diagnostics Research and Development Group at Hybritech Inc., where he was responsible for new product development and was the transfer project leader for ICON® QSR CK-MB, a cardiac marker assay. He is the Chairman of the Board of Sequenom Inc. and Chairman of the Board of Quidel Corp. Dr. Buechler serves as a Director at Sotera Wireless, Inc. and Astute Medical Inc. Dr. Buechler holds a Bachelor degree in Chemistry and a Doctorate in Biochemistry from Indiana University.

Mark Bowles

Salveo DX and ecoATM

Mark Bowles is a serial entrepreneur, award winning inventor (30+ patents apps), product designer (dozens of awards), marketer, and scientist (National Science Foundation grantee/principal investigator). Mark is currently a co-founder at Salveo DX and has 25+ yrs in semiconductor, wireless, healthcare, environmental, consumer/retail industries and has formation and founding 7 tech start-ups for which he has raised 17 rounds of VC financing (nearly $250M). Prior to co-founding Salveo DX, Mark founded ecoATM ($350M acq by Outerwall in 2013); was VP Mktg with Vativ (sold to Entropic); co-founded Staccato in 2002 as VP Mktg & Bus. Dev; co-founder and President/COO and director of BOPS, Inc (sold to Altera). Prior to this he helped form and fund Power Computing (sold to Apple in 1996 for $130M); Panorama Designs (sold to Motorola in 1996); and BlueSteel Networks (sold to Broadcom for $110M in 2000). Mr. Bowles also spent six years at Motorola Semiconductor where he held various distribution management, sales and market development positions; he left Motorola in 1996 as VP MSPI of PowerPC Market Development.

Kirk Malloy Ph.D.

Illumina and Biosite

Dr. Malloy has held management and executive leadership positions in rapidly growing life science and diagnostics companies for over 20 years.  His most recent role was Senior Vice President and General Manager of Life Sciences and Applied Markets at Illumina, a leading developer and supplier of genetic analysis instrumentation, assays and software. In this role he oversaw the company’s core platform technologies and is responsible for a P&L of over $1B serving the life sciences and applied markets (Agrigenomics, Micriobiology, Transplant Biology, Forensics, Complex Diseases and Healthy Genomes).  Prior to joining Illumina in 2002, Malloy built and managed commercial training, support and validation services at Biosite Inc., a leading provider of rapid diagnostics products, where he helped build the point of care cardiovascular diagnostics test market.  Malloy had previously held several commercial management positions at QIAGEN, Inc., a provider of molecular biology reagents for the life sciences, veterinary, diagnostics, and applied markets.  Dr Malloy currently serves on the Board of Directors for Organovo (ONVO), is on the Board of Trustees for the Pacific Ridge School, and is on the Dean’s Advisory Board for the University of Delaware where he completed his M.S. and Ph.D.   He has 12 peer-reviewed publications and book chapters, dozens of invited and contributed scientific presentations and has been a reviewer for various scientific journals.